Arab Journal of Gastroenterology
Volume 11, Issue 2 , Pages 83-87 , June 2010

Chronic hepatitis C genotype 4 treatment in chronic haemodialysis patients: A retrospective study

  • Mohamed Eida

      Affiliations

    • Corresponding Author InformationAddress: Tropical Medicine and Infectious Diseases Unit, Department of Medicine, Suez Canal University, Ismailia, Egypt. Tel.: +20 643343592; fax: +20 643343592.

Received 24 February 2010 ,Accepted 11 April 2010.

References 

  1. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52–61
  2. Fabrizi F, Lunghi G, Raffaele L, et al. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant. 1997;12(2):298–303
  3. Biamino E, Caligaris F, Ferrero S, et al. Prevalence of anti-HCV antibody positivity and incidence of seroconversion in patients undergoing hemodialysis [Prevalenza di positività per anticorpi antiHCV e incidenza di sieroconversione in pazienti in emodialisi] and analysis of costs. Minerva Urol Nefrol. 1999;51(2):53–55
  4. Di Napoli A, Pezzotti P, Di Lallo D, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis. 2006;48(4):629–637
  5. Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant. 1999;14(1):40–45
  6. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65(6):2335–2342
  7. Sezer S, Ozdemir FN, Akcay A, et al. Renal transplantation offers a better survival in HCV-infected ESRD patients. Clin Transplant. 2004;18(5):619–623
  8. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36(1):3–10
  9. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257–263
  10. Bloom RD, Rao V, Weng F, et al. Association of hepatitis C with post transplant diabetes mellitus in renal transplant patients on tacrolimus. J Am Soc Nephrol. 2002;13(5):1374–1380
  11. Fabrizi F, Dulai G, Dixit V, et al. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Therap. 2003;18(11–12):1071–1081
  12. Mousa DH, Abdalla AH, Al Shoail G, et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36(6):1831–1834
  13. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Therap. 2004;20(1):123–124author reply 124
  14. Rivera M, Gentil MA, Sayago M, et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc. 2005;37(3):1424–1425
  15. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13(5):316–321
  16. Russo Mw, Ghalib R, Sigal S, et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis. Nephrol Dial Transplant. 2006;21:437–443
  17. Kokoglu OF, Uçmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21(3):575–580
  18. Teta D, Lüscher BL, Gonvers JJ, et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant. 2005;20:991–993
  19. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16
  20. Zeldis JB, Depner TA, Kuramoto IK, et al. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med. 1990;112:958–960
  21. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4–23years of follow-up. World J Gastroenterol. 2004;10(15):2209–2212
  22. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy and outcome after kidney transplantation. Transplantation. 2004;78(5):745–750
  23. Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20years. Transplantation. 1998;66(4):471–476
  24. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alfa treatment in renal transplant recipients with chronic hepatitis C. Transplantation. 1998;30(7):3270–3272
  25. Cruzado JM, Casanovas Taltavull T, Torras J, et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 2003;3(3):357–360
  26. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after a-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14(8):2092–2098
  27. Covic A, Maftei ID, Mardare NGI, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol. 2006;19(6):794–801
  28. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46(5):768–774
  29. Espinosa M, Arenas MD, Aumente MD, et al. Anemia associated with pegylated interferon-a2a and a2b therapy in hemodialysis patients. Clin Nephrol. 2007;67(6):366–373
  30. Okuda K, Hayashi H, Yokozeki K, et al. Destruction of hepatitis C virus particles by haemodialysis. Lancet. 1996;347(9005):909–910
  31. Hayashi H, Okuda K, Yokosuka O, et al. Adsorption of hepatitis C virus particles onto the dialyzer membrane. Artif Organs. 1997;21(10):1056–1059
  32. Furusyo N, Hayashi J, Ariyama I, et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol. 2000;95(2):490–496

PII: S1687-1979(10)00047-X

doi: 10.1016/j.ajg.2010.04.004

Arab Journal of Gastroenterology
Volume 11, Issue 2 , Pages 83-87 , June 2010

Article Tools

* Image Usage & Resolution